



Nano Emulsion: The Targeted Drug Delivery in the Therapy of Epilepsy

N. V. L. Suvarchala Reddy V. ^{a++*}, M. Ganga Raju ^a,
Keerthana Edunoori ^a and Jyothi Papani ^a

^a Department of Pharmacology, Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, Telangana, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/IRJPAC/2023/v24i5824

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/105367>

Review Article

Received: 20/06/2023

Accepted: 24/08/2023

Published: 02/09/2023

ABSTRACT

Around the world, 50 million people suffer with epilepsy; it significantly burdens society in terms of finances, society, and health. Our comprehension of the pathophysiological processes causing the illness and the factors affecting its prognosis has significantly advanced during the last ten years. Around a third of patients are still resistive to medical intervention, despite the fact that the number of antiepileptic drugs has expanded dramatically over the past 20 years. The ability of nanotech-based anti-epileptic drug (AED) administration methods to cross the blood brain barrier, increase specificity, and have the capacity for extended brain administration of drugs have lately attracted interest. Nanotechnology appears to be a promising and innovative development in this area. Nano emulsions have a mean droplet size of 20 to 200 nm and remain kinetically stable dispersions of two incompatible liquids with the assistance of an emulsifier or emulsifiers. The effectiveness of NEs as a delivery system for Central Nervous System-active medications used in effective regimens against difficult-to-treat CNS conditions.

⁺⁺ Associate Professor;

*Corresponding author: E-mail: suvarchalakiran@gmail.com;

Keywords: Epilepsy; types of seizures; antiepileptic drugs; nanoemulsions.

1. INTRODUCTION

Epi is a Greek prefix, which means "onto," & labein, a Greek verb, which means "to take, grasp, or seize," are the roots of the word "epilepsy" [1]. One can experience epilepsy at any stage in their life, which is a serious worldwide health crisis [2]. It ranks the third most third-most prevalent severe neurological ailment and it is a long-lasting, non-communicable illness of the brain. The stereotyped behavioural abnormalities that characterise epileptic seizures, recurrent paroxysmal instances, which represent the disease's underlying neurological mechanisms [3]. Approximately 50 million people, or One percent of the world's population, suffer from epilepsy, a brain illness that shortens life. Although epilepsy is widespread, 80 percent of patients are found in nations with middle or low incomes [4]. One percent of people have epilepsy in India [5]. The International League against Epilepsy (ILAE) describes a seizure of epilepsy as "a brief episode of signs or symptoms brought on by abnormally excessive or synchronous brain neuronal activity." The idea of epilepsy is described as "a persistent propensity for epileptic seizures in the brain that has negative effects on neurobiology, cognition, psychology, and society" [6].

The pathogenesis of epileptic seizures is frequently attributed to an imbalance caused by the activation of glutamatergic neurotransmission and the inhibition of GABA-mediated neurotransmission in the brain, specifically in the hippocampal, neocortical, corticothalamic, and basal ganglia network [7].

A transient alteration in behaviour caused by extremely aberrant or synchronised neural activity in the brain is known as an epileptic seizure. Both observable symptoms and psychological signs, such as loss of consciousness, jerking, feeling rising from the abdomen towards the chest area, a burnt rubber smell, or a feeling of déjà vu can be present. The start of a seizure could have an unknown onset,

be focal, or be generalised. Almost any injury that disturbs brain function can result in seizures, even though the origin of epilepsy in many people is unknown. There are numerous causes of these injuries, including acquired causes (such as those following a stroke, brain tumour, or brain trauma), infectious circumstances (including meningitis, encephalitis, and also neurocysticercosis), genetic changes, Immune system disorders, and occasionally disrupted levels of substances like sodium or sugar [8].

In addition to significantly higher morbidity and death, it is accompanied by depression and anxiety [4].

1.1 Types of Seizures

The commencement of a seizure can be focal (may initiate in a single region of the brain), generalised (occurring simultaneously in both regions), or undetermined. Based on degree of awareness- measure of consciousness is unharmed or damaged, focal seizures are categorised. nonmotor and motor seizures are further separated into focal and generalised forms [9].

1.1.1 Status epilepticus

Status epilepticus is characterised by seizures lasting less than 30 minutes or by episodes with no remission in between.

1.1.2 Sudden Unexpected Death in Epilepsy (SUDEP)

Sudden unexpected death in epilepsy (SUDEP) is described as a sudden, unexpected, nontraumatic, and nondrowning death in epileptic patients, regardless of the indication of a seizure, apart from reported SE, in which a toxicologic or physical source of death is not identified after postmortem examination. SUDEP is frequently brought on by seizures and seizure-induced alterations in cardiorespiratory performance are a tenable theory [9].

Table 1. Seizure classification

| Focal onset | Generalized onset | Focal onset |
|---------------------------------|---|---|
| Aware or impaired awareness | Motor <ul style="list-style-type: none"> • Tonic-clonic • Other motor | Motor <ul style="list-style-type: none"> • Tonic-clonic • Other motor |
| Motor onset or nonmotor onset | Nonmotor | Nonmotor |
| Focal to bilateral tonic-clonic | | Unclassified |

2. TREATMENT

Epilepsy is currently treated with monotherapy with contemporary antiepileptic medicines, while some cases call for polypharmacy, or the use of two or more anticonvulsants. Regulation of Cl⁻ channel-mediated GABA inhibition of neurotransmitters that are excitatory and irrational neuronal firing are examples of therapeutic approaches. These therapeutic approaches, however, have a wide range of negative side effects [10].

2.1 Antiepileptic Medications (AEDs)

The main goal of AEDs is to stop epileptic episodes. They are also helpful for a variety of non-epileptic disorders and are frequently used as a treatment mental illness, neuropathic pain, and migraine. AEDs can also be helpful therapy of phobias, anxiousness, and syndrome of restless legs, essential tremor, schizophrenia, myotonia, dystonia, essential tremor, myotonia, Chronic stress disorder after trauma, and withdrawal from alcohol and alcoholism [11].

AEDs prevent the spread of aberrant firing, that is required for the manifestation of behavioural seizure activity to distant regions. The extraordinary property of the medications is their ability help control seizures while maintaining normal neurological function. AEDs suppress seizure-related firing without affecting non-epileptic activity via specifically modifying the excitability of neurons by means of a range of molecular targets. This is mostly accomplished via influencing sodium and calcium-voltage-gated channels, or by promoting inhibition through GABA_A (gamma-aminobutyric acid, type A) receptors [11].

Although there are many antiepileptic medications in the market, their effectiveness has been restricted because of adverse effects, poor gastrointestinal absorption, drug resistance, BBB penetration, and plasma protein binding [12].

2.2 Other Treatments Include

Drug-resistant epilepsy, Emergency treatments, Surgical procedure, Medical intervention, Neurostimulation [6].

3. CHALLENGES FOR TARGETING DRUG TO BRAIN

Central nervous system (CNS) problems and other brain diseases rank among the most common, deadly, and undertreated illnesses. Contrary to other therapeutic fields, developing medications for brain disorders has the lowest success rates. The BBB, adverse effects, and complexity of the brain make clinical trials of CNS medications difficult. CNS medication development is hampered by the intricacy of brain illnesses as well as the lack of effective BBB drug delivery technology. The BBB prevents the majority of macromolecules from penetrating the brain endothelium; but tiny molecules which are lipophilic in nature and having a molecular weight of 400 Da or less can penetrate and cross the BBB. 95% of compounds intended for therapeutic development are thwarted by the BBB's physiological barrier. Recent research has shown that the BBB is a dynamic interface that regulates which chemicals enter the brain via the circulatory system. These developments both highlight the necessity to reevaluate some notions about brain drug administration and open up huge possibilities for brand-new drug delivery techniques [13].

Numerous approaches, including pharmacological (e.g., chemical drug delivery, liposomes, nano-conjugates, and nanoparticles), physiological (e.g., pseudo nutrients, chimeric peptides, and ligand binding proteins), and invasive (e.g., intracerebral implants, BBB disruption), are being considered for the targeted delivery of drug molecules into the brain. Nes have broad application in bioavailability as well as in its delivery by various routes like oral, parental, nasal route, and ocular [14].

Table 2. Classification of AEDs

| Type of Seizures | Drugs |
|---|---|
| Focal seizures and most Generalised seizure types | Benzodiazepines, Phenobarbital, Levetiracetam, Lamotrigine, Topiramate, Felbamate, primidone and Valproic acid, |
| Focal seizures, with or without Secondary generalisation: | phenytoin, Gabapentin, Carbamazepine, tiagabine, Lacosamide, pregabalin, Vigabatrin. |
| Absence seizures | Ethosuximide |

Restrictive barriers like the BBB and BCSFB make it difficult to deliver medications to the brain for the treatment of brain diseases [15]. Emulsion nanomedicine has unique biological interactions, enhanced bioavailability, stability against degradation, and lower clearance over free drug [16]. Nes can be directed at the brain from the body via a variety of paths because of their small size and hydrophilic-lipophilic characteristics [15].

4. NANOEMULSION

About 20 and 40% of epileptic individuals still experience medically intractable epilepsy, despite major advancements in recent decades. About 70% of AEDs are successful, yet there are still a lot of problems that require to be fixed counting inadequate bioavailability, solubility, blood-brain barrier (BBB) permeability, high cost, unavailability, and unpleasant effects [17]. Since traditional medicines have a low bioavailability and eventually lose their effectiveness as therapy goes on owing to drug resistance, managing epilepsy with them can be difficult. Appropriate drug delivery methods can alleviate the difficulties in treating epilepsy caused by the current AEDs' inability to traverse the nearby BBB. Systems built on nanotechnology appear to

be an innovative and promising improvement in this area. Using customised nanocarriers to target drug molecules to the brain is a new method of selectively delivering medications to the brain [5].

Nanoemulsions are created delivery devices for biologically active substances for controlled release and drug delivery [18]. Due to their ability to improve solubility of lipid soluble medicines, penetration through biological membranes, and efficacy in therapy because of their predictable shape distribution, high loading of drugs, and endurance in biological systems, Due to the nanometre-sized droplet width of NE, these formulations have attracted a lot of attention as drug delivery systems for lipophilic medications. [19].

NE are thermally stable and isotropic, homogeneous system of water, oil and surfactants/co-surfactants. NE droplet sizes (o/w and w/o) range from 20 to 200 nm [20]. Over traditional formulations, the NE system has a number of advantages. One of the best methods for making lipophilic medications more water soluble is NE, which also improves the drug's bioavailability in the bloodstream [21]. Drug




Fig. 1. Types of nanoemulsion

distribution (targeted and sustained) depends heavily on the transport characteristics of the drug, which are affected by the nanoscale droplets' larger interfacial areas [19].

Water in oil NE, droplets of water scattered over a phase of continuous oil and bi-continuous NE are the three forms of NE that can form [18]. When oil is spread in the continuous aqueous phase, oil in water NE occurs. To create NE, many methods include, ultrasonication, phase inversion temperature, high pressure homogenization, emulsion inversion point, and more newly found methods like the bubble bursting method are employed [22].

4.1 Formulations of Nanoemulsion

4.1.1 Topiramate

A broad spectrum anti-epileptic medication called topiramate has been licenced in the treatment of both focal and tonic-clonic seizures. The brain bioavailability of topiramate is low following oral delivery during an epileptic seizure. The main dose-related adverse event with TPM use is severe weight loss. This study demonstrated that increasing brain bioavailability with intranasal administration of topiramate-containing NE is possible. The findings of this study provided a strong foundation for developing a TPM-containing NE formulation and putting it to use in clinical settings [23].

4.1.2 Letrozole (LET)

To decrease the negative effects of LET on the peripheral nervous system, Iqbal and colleagues created a NE for letrozole to be delivered nose-to-brain. In mice with SE caused by kainic acid, the new formulation was contrasted with intraperitoneally administered free medication. Because of direct nose-to-brain transport, LET-NE treatment intraperitoneally increased absorption compared to the i.p. method. Only with LET-NE were additional neuroprotective effects seen. When given as an intranasal NE, LET was found to be present in higher concentrations in the mouse brain during gamma scintigraphy investigations. Histopathological studies and behavioural monitoring showed that LET-NE's anticonvulsant activity was greater to LET's [24].

4.1.3 Amiloride

Amiloride to surge the brain's ability to absorb amiloride, an amiloride NE was created utilising a

combination of the high energy ultrasonication method and aqueous micro titration method. It was found that formulation had a highly significant, targeting potential and efficiency, which means that amiloride is now more bioavailable in the brain. Assessment of in vivo data for biodistribution, pharmacokinetics, effectiveness of brain targeting, and transport were used to support this claim [25].

4.1.4 *Centella asiatica* (*C. asiatica*)

The Ayurvedic medicine *C. asiatica* has been used to treat epilepsy. They created a NE that contained *C. asiatica* crude extract, and research has shown that it is a promising formulation that should be used in future studies for a pharmaceutical use, specifically for the management of epilepsy [26].

4.1.5 β -Caryophyllene

β -Caryophyllene is a typical natural phenomenon cannabinoid receptor activator with possible anticonvulsant effects but low oral bioavailability. They used Pentylene tetrazole (PTZ)-induced seizure model to establish and define NE and its possible antiepileptic activity when administered intravenously to rats. By means of spontaneous emulsification, β -Caryophyllene-NE was created. A study conducted in vivo showed up *i.n.* NE treatment postponed the beginning of grand mal seizure. These outcomes showed that NE given through the *i.n.* pathway has the possibility to be anticonvulsant, demonstrating that the proposed approach provides effective intranasal BCP delivery [27].

4.1.6 Other Examples

Valproic acid loaded NE, Gabapentin loaded optimised NE, Phenytoin NE, Carbamazepine NE, Rutin NE, Cannabidiol NE. Herbal Formulations include *Centella asiatica* NE, NE of Safranol.

4.2 Advantages

1. By enhancing lipid solubility, it improves transport to the brain [28].
2. It increases the drug's bioavailability [29].
3. Non-irritating and not harmful.
4. NEs have small droplets with more surface area, which boosts absorption.
5. The huge NE interfacial area facilitates the delivery of the medicine or active component to the desired spot.

6. Effective at disguising flavour.
7. NEs can be used to produce both hydrophobic and hydrophilic medications [30].
8. Drugs that are prone to oxidation and hydrolysis may also be protected by NE [31].
9. Improve the profile of pharmacokinetics [27,32].

4.3 Disadvantages

1. Lack of stability is the biggest drawback of NE's [33].
2. Several debilitating processes, such as, including coalescence, ostwald ripening, flocculation, and creaming/sedimentation, cause NE to gradually divide into various phases over time [4].

4.4 Advantages of NE's Over Conventional Formulations

1. Maximum utilisation of drug.
2. Enhanced bioavailability.
3. Minimized side-effects.
4. Preventing enzymatic, chemical, and physical degradation of the medication.
5. Improved patient comfort and compliance.
6. An increase in the high potency drug margin.

5. CONCLUSION

Since neurological problems are becoming more common, there will eventually be a greater need for enhanced CNS therapies. With the help of epilepsy research, researchers have made incredible strides in understanding the risk factors and mechanisms behind epilepsies and comorbidities, as well as developing strategies and medications that will help us better manage seizures and any comorbid illnesses or side effects they may cause. However, there are still a lot of steps to be taken in order to provide efficient treatments that can enhance quality of life while preventing epilepsy and associated comorbidities. Approaches based on nanotechnology provide potentially efficient ways to enhance seizure identification and management. Particularly for the BBB, this poses a challenging obstacle to the transport of drugs to the brain, nanotherapeutics can be a potential vehicle. Effectiveness, safety, and enhanced bioavailability can all be attributed to NE formulation.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Avanthi E, Pradeep Kumar L, Lokesh BN, Yadavalli Guruprasad. The study of antiepileptic activity of clove oil by MES model in mice. *Indian Journal of Pharmacy and Pharmacology*. 2016;3(3); 103-107.
2. World Health Organization. Global status report on alcohol and health 2018. World Health Organization; 2019.
3. Neligan A, Hauser WA, Sander JW. The epidemiology of the epilepsies. *Handbook of clinical neurology*. 2012;107:113-33.
4. Ghosh S, Sinha JK, Khan T, Devaraju KS, Singh P, Vaibhav K, Gaur P. Pharmacological and therapeutic approaches in the treatment of epilepsy. *Biomedicines*. 2021;9(5):470.
5. Shringarpure M, Gharat S, Momin M, Omri A. Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery. *Expert Opinion on Drug Delivery*. 2021;18(2):169-85.
6. Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. *The Lancet*. 2015;385(9971):884-98.
7. Birhan YS. Medicinal plants utilized in the management of epilepsy in Ethiopia: ethnobotany, pharmacology and phytochemistry. *Chinese Medicine*. 2022;17(1): 1-37.
8. Devinsky O, Vezzani A, O'Brien TJ, Jette N, Scheffer IE, de Curtis M, Perucca P. Epilepsy (primer). *Nature Reviews: Disease Primers*. 2018;4(1).
9. Beghi E. The epidemiology of epilepsy. *Neuroepidemiology*. 2020;54(2):185-91.
10. Patil MV, Kandhare AD, Ghosh P, Bhise SD. Determination of role of GABA and nitric oxide in anticonvulsant activity of *Fragaria vesca* L. ethanolic extract in chemically induced epilepsy in laboratory animals. *Oriental Pharmacy and Experimental Medicine*. 2012;255- 64.
11. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. *Nature reviews neuroscience*. 2004;5(7):553-64.

12. El-Missiry MA, Othman AI, Amer MA, Sedki M, Ali SM, El-Sherbiny IM. Nanoformulated ellagic acid ameliorates pentylenetetrazol-induced experimental epileptic seizures by modulating oxidative stress, inflammatory cytokines and apoptosis in the brains of male mice. *Metabolic Brain Disease*. 2020;35:385-99.
13. Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. *Journal of Biomaterials and Nanobiotechnology*. 2011;2(05):626.
14. Nirale P, Paul A, Yadav KS. Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's. *Life sciences*. 2020;245:117394.
15. Wilson RJ, Li Y, Yang G, Zhao CX. Nanoemulsions for drug delivery. *Particuology*. 2022;64:85-97.
16. Harun SN, Nordin SA, Gani SS, Shamsuddin AF, Basri M, Basri HB. Development of nanoemulsion for efficient brain parenteral delivery of cefuroxime: Designs, characterizations,
17. Sepasi T, Ghadiri T, Bani F, Ebrahimi-Kalan A, Khodakarimi S, Zarebkohan A, Gorji A. Nanotechnology-based approaches in diagnosis and treatment of epilepsy. *Journal of Nanoparticle Research*. 2022; 24(10):199.
18. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. *3 Biotech*. 2015;123-7.
19. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. *Journal of Drug Delivery and Therapeutics*. 2019;9(2):520-7.
20. Harwansh RK, Deshmukh R, Rahman MA. Nanoemulsion: Promising nanocarrier system for delivery of herbal bioactives. *Journal of Drug Delivery Science and Technology*. 2019;51:224-33.
21. Kumar M, Bishnoi RS, Shukla AK, Jain CP. Techniques for formulation of nanoemulsion drug delivery system: a review. *Preventive nutrition and food science*. 2019;24(3):225.
22. Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: formation, properties and applications. *Soft matter*. 2016;12(11): 2826-41.
23. Patel RJ, Parikh RH. Intranasal delivery of topiramate nanoemulsion: Pharmacodynamic, pharmacokinetic and brain uptake studies. *International Journal of Pharmaceutics*. 2020;585:119486.
24. Iqbal R, Ahmed S, Jain GK, Vohora D. Design and development of letrozole nanoemulsion: A comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice. *International journal of pharmaceutics*. 2019;565:20-32.
25. Ahmad N, Ahmad R, Alam MA, Ahmad FJ, Amir M. Retracted Article: Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. *Artificial Cells, Nanomedicine, and Biotechnology*. 2018; 46(Sup 3):192-207.
26. Thuraisingam S, Salim N, Azmi ID, Kartinee N. Development of nanoemulsion containing *Centella asiatica* crude extract as a promising drug delivery system for epilepsy treatment. *Biointerface Res. Appl. Chem*. 2022;13(17):10-33263.
27. Nogueira C, Lemos-Senna E, da Silva Vieira E, Sampaio TB, Mallmann MP, Oliveira MS, Bernardi LS, Oliveira PR. β -caryophyllene cationic nanoemulsion for intranasal delivery and treatment of epilepsy: development and *in vivo* evaluation of anticonvulsant activity. *Journal of Nanoparticle Research*. 2023; 25(1):19.
28. Chircov C, Grumezescu AM. Nanoemulsion preparation, characterization, and application in the field of biomedicine. In *Nanoarchitectonics in biomedicine*. 2019;169-188. William Andrew Publishing.
29. Kim CK, Cho YJ, Gao ZG. Preparation and evaluation of biphenyl dimethyl dicarboxylate microemulsions for oral delivery. *Journal of controlled release*. 2001;70(1-2):149-55.
30. Simonazzi A, Cid AG, Villegas M, Romero AI, Palma SD, Bermúdez JM. Nanotechnology applications in drug controlled release. In *Drug targeting and stimuli sensitive drug delivery systems*. William Andrew Publishing. 2018;81-116.
31. Nishitani Yukuyama M, Tomiko Myiake Kato E, Lobenberg R, Araci Bou-Chacra N. Challenges and future prospects of nanoemulsion as a drug delivery system. *Current Pharmaceutical Design*. 2017; 23(3):495-508.

32. Halnor VV, Pande VV, Borawake DD, Nagare HS. Nanoemulsion: A novel platform for drug delivery system. J Mat Sci Nanotechol. 2018;6(1):104.
33. Vashi K, Pathak YY. Challenges in targeting to brain and brain tumors. In Nanocarriers for Drug-Targeting Brain Tumors. Elsevier. 2022;51-68.

© 2023 Reddy et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/105367>